Author Archives: admin


Stem Cell Clinic > Articles by: admin

Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights

By Global News Feed

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2022 financial results and corporate highlights after the close of market on Thursday, May 5, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release.

Visit link:
Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights

Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022

By Global News Feed

FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11th, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

Continue reading here:
Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

By Global News Feed

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company, merger or reverse merger.

Excerpt from:
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

Travere Therapeutics to Report First Quarter 2022 Financial Results

By Global News Feed

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Continued here:
Travere Therapeutics to Report First Quarter 2022 Financial Results

Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022

By Global News Feed

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2022, before the US markets open on Monday, May 9, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.

Read more from the original source:
Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

By Global News Feed

JUPITER, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the first quarter 2022 and host a corporate update conference call on Thursday, May 12, 2022.

Excerpt from:
Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

By Global News Feed

MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announced private placement pursuant to a securities purchase agreement entered into on April 25, 2022 with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

Read more:
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results

By Global News Feed

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2022 financial results after the U.S. financial markets close on Thursday, May 5, 2022. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial results.

Read this article:
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results

→←